We seek completely new therapeutic effects and cures through innovative drugs. We believe that it takes a community to build a great medicine. Using our website and other media, we provide information and create venues for patients, caregivers, researchers and pharmaceutical manufacturers to communicate with each other, accelerating worldwide cancer treatment development. We believe that initiatives such as these are a must for Lyvgen.
Lyvgen’s mission is to obtain regulatory approval for drugs that extend and improve the lives of cancer patients, by:
Why Lyvgen as a Partner
Lyvgen is today a well-established biopharmaceutical company that thanks to its own R&D activities, to partnerships and acquisitions has grown into an International player with a strong and growing interest in oncology.
What we are looking for
Stage: After proof-of-concept step, Phase II or later stage
Formulation: Small molecule or Biological products or others, no limit
Methods: Chemotherapy, Radiotherapy, Immunotherapy or others, no limit
Indication: Cancer, ideally the cancers with high prevalence or morbidity in China.
2019: Lyvgen established a relationship with Merck (MSD) through a new strategic collaboration to initiate Phase I clinical trial of anti-CD137 (LVGN6051) combined with pembrolizumab (anti-PD-1)
2018: Lyvgen signed Collaborative Agreement with Boehringer Ingelheim for the manufacture and global supply of agonist anti-CD137 antibody